62 FINANCIAL REPORT NOTES TO THE FINANCIAL STATEMENTS CONTINUED 30 June 2023 Note 15. Trade and other payables Consolidated 2023 2022 $ $ Current liabilities Trade payables 857,312 1,524,174 Accrued payables 3,471,637 2,235,946 4,328,949 3,760,120 Refer to note 23 for further information on financial instruments. Note 16. Borrowings Consolidated 2023 2022 restated $ $ Current liabilities Insurance premium funding 1,796,500 1,841,052 Refer to note 23 for further information on financial instruments. Note 17. Employee benefits Consolidated 2023 2022 $ $ Current liabilities Annual leave 488,775 368,616 Employee benefits 201,027 - 689,802 368,616 Non-current liabilities Long service leave 59,323 116,596 749,125 485,212 Note 18. Contingent consideration Consolidated 2023 2022 restated $ $ Current liabilities Contingent consideration – paxalisib 750,000 - Contingent consideration – EVT801 - 758,840 750,000 758,840 Non-current liabilities Contingent consideration – paxalisib 653,692 1,167,536 Contingent consideration – EVT801 5,467,091 7,041,409 6,120,783 8,208,945 6,870,783 8,967,785
RkJQdWJsaXNoZXIy MjE2NDg3